tiprankstipranks
Trending News
More News >

Thiogenesis Launches Phase 2 Trial for MELAS Treatment

Story Highlights
Thiogenesis Launches Phase 2 Trial for MELAS Treatment

Don’t Miss TipRanks’ Half-Year Sale

Thiogenesis Therapeutics Corp ( (TSE:TTI) ) has shared an update.

Thiogenesis Therapeutics Corp has initiated a Phase 2 clinical trial for its lead product candidate, TTI-0102, aimed at treating the mitochondrial disease MELAS. The trial, conducted in the Netherlands and France, will assess the safety and efficacy of TTI-0102, a prodrug designed to increase antioxidant levels in patients, potentially addressing a significant unmet need in the treatment of MELAS, a prevalent yet orphan mitochondrial disorder.

More about Thiogenesis Therapeutics Corp

Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company based in San Diego, California. It focuses on developing disulfides that enhance the production of intracellular antioxidants and therapeutic compounds, with a market focus on treating inherited mitochondrial diseases.

Average Trading Volume: 29,325

Technical Sentiment Signal: Sell

Current Market Cap: C$30.1M

See more insights into TTI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1